Effectiveness of myofascial release on pain, sleep, and quality of life in patients with fibromyalgia syndrome: A systematic review.

Fibromyalgia syndrome involves widespread pain, poor sleep, and reduced quality of life, and this systematic review asked whether myofascial release, a manual therapy technique targeting connective tissue, helps with these symptoms. The authors searched multiple databases through April 2021 and pooled data from six studies totaling 279 participants, comparing therapist-delivered or self-administered myofascial release against sham treatment or no treatment. The meta-analysis found a large statistically significant reduction in pain immediately after treatment and a moderate effect that persisted at six months. The review describes moderate evidence for benefits on pain, sleep subscales, and quality of life, but the authors note that more high-quality randomized trials with proper manual control groups, conducted across different geographic locations, are needed before findings can be generalized.

Risk of bias was assessed using a standard tool, though the abstract does not specify overall study quality ratings.

If you live with fibromyalgia, a condition that causes widespread pain, sleep problems, and can affect daily quality of life, you may wonder whether hands-on treatments like myofascial release, a technique that works on the connective tissue around muscles, could help. This review pulled together six studies with 279 participants total to look at exactly that question, comparing myofascial release (done by a therapist or by patients themselves) to sham treatments or no treatment at all. The combined results showed a large reduction in pain right after treatment, and this benefit was still present, though somewhat smaller, six months later.

The review also found evidence pointing to improvements in sleep and quality of life. That said, the authors describe this as moderate evidence, not definitive proof, and they specifically call for more well-designed studies with proper comparison groups conducted in different parts of the world before the findings can be considered widely applicable.

So while the results are encouraging on paper, the evidence base is still developing.

This is a summary of research, not medical advice. Talk to your own healthcare provider about anything affecting your care.

This systematic review and meta-analysis pooled six studies (n=279) evaluating myofascial release, either therapist-administered or self-administered, against sham or no-treatment controls in fibromyalgia syndrome. Databases searched included PubMed, Scopus, Cochrane Library, PEDro, Embase, Web of Science, CINAHL Complete, and ProQuest, through April 2021, with risk of bias assessed via Cochrane RoB 2.0. Pooled effects showed a large statistically significant reduction in pain post-treatment (SMD -0.81, 95% CI -1.15 to -0.47) and a moderate effect maintained at six-month follow-up (SMD -0.61, 95% CI -0.95 to -0.28).

The authors characterize the overall evidence as moderate for effects on pain, sleep subscales, and quality of life, but this rests on a small pool of six trials with heterogeneous comparators, sham versus no-treatment control conditions differ substantially in their ability to control for placebo and attention effects. The authors explicitly call for additional high-quality randomized controlled trials using proper manual control groups and conducted across varied geographic settings to improve generalizability. No adverse events were reported in the abstract.

Clinicians should interpret the moderate certainty rating and limited trial number as indicating a promising but still provisional evidence base.